|
 |
| |
 |
 |
| |
ThermoGenesis is pursuing significant
revenue opportunities in the Hospital/Wound Care and Blood Processing
markets by providing those cutting edge technological solutions
that meet the needs of blood processing centers and surgical
suites. We expect our existing products, as well as those under
development, to generate attractive financial returns for our
stockholders, while improving the lives of patients throughout
the world.
|
 |
| |
ThermoGenesis products derived from
the BioArchive® and CryoSeal® technology platforms (following
regulatory approval) will provide significant revenue and gross
profit growth in years to come. These products will meet the
growing need for therapeutic doses of cellular or wound-healing
protein and growth-factor products, which can be micro-manufactured
from individual units of blood. We continue to pursue an aggressive
intellectual property portfolio to ensure that we retain the
competitive advantage that our novel, micro manufacturing platform
technologies have gained for us.
|
| |
 |
 |
| |
Our strategy for penetrating the vast Blood Processing
Market relies on our technologies for manufacturing cell therapy
products (compliant with FDA cGMP regulations). This market
is estimated to reach $440 million by 2010. Towards this end,
the Company has moved beyond its traditional blood component
freezing and thawing products with the BioArchive® System
- a computer-controlled, robotic liquid nitrogen cryopreservation
and storage system - and the AXP™ System, a miniaturized,
semi-automated system for blood cell separation, blood cell
processing, and inventory tracking. |
 |
 |
| |
ThermoGenesis entered the $680 million Hospital/Wound
Care market with its CryoSeal® FS fibrin sealant system.
The system is currently engaged in a Phase III clinical trial
in the United States, as well as multiple field trials in Europe,
Asia, South America and Canada. The Company was the first in
the world to produce a system capable of creating 100% autologous
fibrin sealant from a single unit of a patient’s blood
plasma, in approximately 60 minutes. We have expanded this technology
to create the stand-alone Thrombin Processing Device (TPD™),
a small, handheld disposable which provides 100% autologous
human thrombin from a small volume of patient blood, in the
Operating Room, in less than 30 minutes.
|
|
| |
 |
| The statements contained
in this website which are not historical facts are forward-looking
statements subject to risks and uncertainties that could
cause actual results to differ materially from those expressed
in the forward-looking statements, including, but not
limited to, certain delays beyond the company's control,
with respect to market acceptance of new technologies
and products, delays in testing and evaluation of products,
and other risks detailed from time to time in the Company's
filings with the Securities and Exchange Commission. |
|
| |
 |
|
|
